Skip to main content
. 2023 May 12;38(7):1316–1326. doi: 10.1002/mds.29421

FIG 2.

FIG 2

Progressive supranuclear palsy (PSP) Rating Scale on the left and Addenbrooke's Cognitive Examination–Revised (ACE‐R) scores on the right in 48 patients (PSP = 32, corticobasal degeneration [CBD] = 16) versus symptom duration, at baseline (circles) and at follow‐up (triangles) in 22 patients (PSP = 16, CBD = 6). Each colored line represents a patient who completed the follow‐up arm of the study. [Color figure can be viewed at wileyonlinelibrary.com]